The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Treating CLL after venetoclax or BTK inhibitors
Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the treatment options for chronic lymphocytic leukemia (CLL) patients who relapse after venetoclax or BTK inhibitors. Dr Mazyar specifically discusses how later lines ought to be considered early, and also mentions potential strategies the future could hold, such as CAR-T. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
